Newsroom
News & Media
Dec2020
15
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study
Nov2020
09
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
Sep2020
29
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Aug2020
25
Prometheus Biosciences Appoints Joseph C. Papa to its Board of Directors
Aug2020
13
Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
Aug2020
04
Prometheus Biosciences Appoints Keith W. Marshall as Chief Financial Officer
Dec2019
10
Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer
Oct2019
03
Prometheus Biosciences, Inc., Enters Into Multi-Target Strategic Collaboration with Takeda to Develop Targeted Therapies for Inflammatory Bowel Disease
Oct2019
02
Prometheus Biosciences Strengthens Executive Management Team with New Appointments
Sep2019
05